| AASLD

Circulating MicroRNA‐122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD

Read more about Circulating MicroRNA‐122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD

Norio Akuta, Yusuke Kawamura, Yasuji Arase, Satoshi Saitoh, Shunichiro Fujiyama, Hitomi Sezaki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Yoshiyuki Suzuki, Fumitaka Suzuki, Kenji Ikeda, Hiromitsu Kumada – 5 November 2019 – The impact of circulating microRNA‐122 (miR‐122) on mortality in patients with histopathologically confirmed nonalcoholic fatty liver disease (NAFLD) remains unclear. We analyzed the overall survival rates in 441 Japanese patients with histopathologically confirmed NAFLD after a median follow‐up period of 4.7 years.

Multiparametric Magnetic Resonance Elastography Improves the Detection of NASH Regression Following Bariatric Surgery

Read more about Multiparametric Magnetic Resonance Elastography Improves the Detection of NASH Regression Following Bariatric Surgery

Alina M. Allen, Vijay H. Shah, Terry M. Therneau, Sudhakar K. Venkatesh, Taofic Mounajjed, Joseph J. Larson, Kristin C. Mara, Todd A. Kellogg, Michael L. Kendrick, Travis J. McKenzie, Suzanne M. Greiner, Jiahui Li, Kevin J. Glaser, Michael L. Wells, Timothy J. Gunneson, Richard L. Ehman, Meng Yin – 5 November 2019 – Disease monitoring in nonalcoholic steatohepatitis (NASH) is limited by absence of noninvasive biomarkers of disease regression or progression.

Something Wicked this Way Comes

Read more about Something Wicked this Way Comes

Timucin Taner, Julie K. Heimbach – 4 November 2019

Letter to the Editor: Modest Alcohol Consumption and Nonalcoholic Fatty Liver Disease: An Oxymoron?

Read more about Letter to the Editor: Modest Alcohol Consumption and Nonalcoholic Fatty Liver Disease: An Oxymoron?

Alain Braillon – 4 November 2019

Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid

Read more about Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid

John E. Eaton, Raj Vuppalanchi, Rajender Reddy, Sanjaya K. Satapathy, Bilal Ali, Patrick S. Kamath – 4 November 2019

Reply:

Read more about Reply:

Kaveh Hajifathalian, Babak Torabi Sagvand, Arthur McCullough – 4 November 2019

Liver Fat and Cardiometabolic Risk Factors Among School‐Age Children

Read more about Liver Fat and Cardiometabolic Risk Factors Among School‐Age Children

Madelon L. Geurtsen, Susana Santos, Janine F. Felix, Liesbeth Duijts, Meike W. Vernooij, Romy Gaillard, Vincent W.V. Jaddoe – 4 November 2019

Deficiency in Embryonic Stem Cell Marker Reduced Expression 1 Activates Mitogen‐Activated Protein Kinase Kinase 6–Dependent p38 Mitogen‐Activated Protein Kinase Signaling to Drive Hepatocarcinogenesis

Read more about Deficiency in Embryonic Stem Cell Marker Reduced Expression 1 Activates Mitogen‐Activated Protein Kinase Kinase 6–Dependent p38 Mitogen‐Activated Protein Kinase Signaling to Drive Hepatocarcinogenesis

Steve T. Luk, Kai‐Yu Ng, Lei Zhou, Man Tong, Tin‐Lok Wong, Huajian Yu, Chung‐Mau Lo, Kwan Man, Xin‐Yuan Guan, Terence K. Lee, Stephanie Ma – 4 November 2019

Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid

Read more about Liver Injury in Patients With Cholestatic Liver Disease Treated With Obeticholic Acid

John E. Eaton, Raj Vuppalanchi, Rajender Reddy, Sanjaya K. Satapathy, Bilal Ali, Patrick S. Kamath – 4 November 2019

A Pilot Genome‐Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH

Read more about A Pilot Genome‐Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH

Samer Gawrieh, Xiuqing Guo, Jingyi Tan, Marie Lauzon, Kent D. Taylor, Rohit Loomba, Oscar W. Cummings, Sreekumar Pillai, Pallav Bhatnagar, Kris V. Kowdley, Katherine Yates, Laura A. Wilson, Yii‐Der Ida Chen, Jerome I. Rotter, Naga Chalasani, NASH Clinical Research Network – 3 November 2019 – A significantly higher proportion of patients with nonalcoholic steatohepatitis (NASH) who received obeticholic acid (OCA) had histological improvement relative to placebo in the FLINT (farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, NASH treatment) trial.

Subscribe to